Braveheart Bio
Clinical-stage biopharma developing an oral cardiac myosin inhibitor for people with hypertrophic cardiomyopathy
Highlights
- New on EvolcAdded 2026-11-14
Recent signals
What changed at Braveheart Bio in the last 6 months, newest first. Each line links to its public source.
- 6 Nov 2026 Leadership hire · Hiring Director/Senior Director, Clinical Quality (San Francisco) job-boards.greenhouse.io
- 21 Oct 2026 Leadership hire · Hiring Associate Director/Director, Medical Affairs (San Francisco) job-boards.greenhouse.io
- 20 Oct 2026 Leadership hire · Hiring (Senior) Director, Regulatory Affairs CMC (San Francisco) job-boards.greenhouse.io
About Braveheart Bio
Braveheart Bio develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM) and related conditions. The drug is in two global Phase 3 programs: LIONHEART-HCM in obstructive HCM and NOBLEHEART-HCM in non-obstructive HCM. More than 300 clinical study participants have been dosed with BHB-1893 to date.
The company holds exclusive rights to develop and commercialize BHB-1893 worldwide outside Greater China, under a license from Jiangsu Hengrui Pharmaceuticals, which discovered the molecule and continues its development in Greater China. The target patients are people with obstructive and non-obstructive HCM, a population the company estimates at more than 700,000 in the U.S.
Braveheart Bio launched in 2025 and is listed on the Nasdaq Global Market under the ticker BRVE. Its leadership team includes Chief Executive Officer Travis Murdoch, M.D. Open roles span regulatory affairs, clinical quality, clinical science, clinical operations, medical affairs and finance, listed for San Francisco, CA, remote or hybrid.
Product: BHB-1893, an oral cardiac myosin inhibitor in global Phase 3 development for obstructive and non-obstructive hypertrophic cardiomyopathy.
Jobs at Braveheart Bio
Open roles at Braveheart Bio in the Americas (3)
United States 3. From Braveheart Bio's careers page or applicant tracking system; each role links to the employer.
- (Senior) Director, Regulatory Affairs CMC · San Francisco, United States
- Director/Senior Director, Clinical Quality · San Francisco, United States
- Associate Director, Clinical Science · San Francisco, United States
More biotech & pharma companies
BridgeBio Pharma
Develops drugs for rare genetic conditions, including ATTR amyloidosis, achondroplasia and muscular dystrophyGrowingRemote-friendlyBristolmyerssquibb
Discovers, develops and supplies medicines for patients with serious diseases worldwideCalico
Biology research and drug development targeting aging and age-related diseases for patients and clinical partnersNew on EvolccAMPfield Therapeutics
Clinical-stage biopharma developing prifemilast, an oral PDE4B inhibitor, for ulcerative colitis and Crohn's diseaseYoung companyNew on EvolcCapable Labs
AI-driven therapeutics developer building peptide and RNA drugs, starting with sleep disorder programsNew on EvolcCelcuity
Develops targeted cancer therapies for patients with cancers involving the PAM pathwayNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Response headerserver
- Response headerserver
Content management
- WebflowHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
